• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核酸模板与 PCR 诱导的 HIV-1 耐药突变的风险。

Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.

机构信息

Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.

出版信息

PLoS One. 2010 Jun 7;5(6):e10992. doi: 10.1371/journal.pone.0010992.

DOI:10.1371/journal.pone.0010992
PMID:20539818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2881873/
Abstract

BACKGROUND

The HIV-1 nucleoside RT inhibitor (NRTI)-resistance mutation, K65R confers intermediate to high-level resistance to the NRTIs abacavir, didanosine, emtricitabine, lamivudine, and tenofovir; and low-level resistance to stavudine. Several lines of evidence suggest that K65R is more common in HIV-1 subtype C than subtype B viruses.

METHODS AND FINDINGS

We performed ultra-deep pyrosequencing (UDPS) and clonal dideoxynucleotide sequencing of plasma virus samples to assess the prevalence of minority K65R variants in subtype B and C viruses from untreated individuals. Although UDPS of plasma samples from 18 subtype C and 27 subtype B viruses showed that a higher proportion of subtype C viruses contain K65R (1.04% vs. 0.25%; p<0.001), limiting dilution clonal sequencing failed to corroborate its presence in two of the samples in which K65R was present in >1.5% of UDPS reads. We therefore performed UDPS on clones and site-directed mutants containing subtype B- and C-specific patterns of silent mutations in the conserved KKK motif encompassing RT codons 64 to 66 and found that subtype-specific nucleotide differences were responsible for increased PCR-induced K65R mutation in subtype C viruses.

CONCLUSIONS

This study shows that the RT KKK nucleotide template in subtype C viruses can lead to the spurious detection of K65R by highly sensitive PCR-dependent sequencing techniques. However, the study is also consistent with the subtype C nucleotide template being inherently responsible for increased polymerization-induced K65R mutations in vivo.

摘要

背景

HIV-1 核苷逆转录酶抑制剂(NRTI)耐药突变 K65R 赋予了对 NRTIs 阿巴卡韦、地达诺辛、恩曲他滨、拉米夫定和替诺福韦的中至高耐药性;对司他夫定则表现出低水平耐药性。有几项证据表明,与 B 亚型病毒相比,K65R 在 C 亚型 HIV-1 中更为常见。

方法与发现

我们采用超深度焦磷酸测序(UDPS)和克隆双脱氧核苷酸测序法对未经治疗个体的血浆病毒样本进行检测,以评估 B 型和 C 型病毒中少数 K65R 变体的流行率。尽管对 18 株 C 亚型和 27 株 B 亚型病毒的血浆样本进行 UDPS 检测显示,C 亚型病毒中 K65R 的比例更高(1.04%比 0.25%;p<0.001),但限制稀释克隆测序未能证实 UDPS 检测结果为 1.5%以上的两份样本中 K65R 的存在。因此,我们对包含 RT 密码子 64 到 66 位保守 KKK 基序中 B 型和 C 型特异性沉默突变模式的克隆和定点突变体进行了 UDPS 检测,发现 C 型病毒中特定于亚型的核苷酸差异是导致聚合酶链反应(PCR)诱导 K65R 突变增加的原因。

结论

本研究表明,C 型病毒中的 RT KKK 核苷酸模板可能导致高度敏感的 PCR 依赖测序技术错误检测到 K65R。然而,该研究也与 C 型核苷酸模板在体内固有地导致聚合诱导 K65R 突变增加的说法一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1b1/2881873/9431603f0d2a/pone.0010992.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1b1/2881873/9431603f0d2a/pone.0010992.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1b1/2881873/9431603f0d2a/pone.0010992.g001.jpg

相似文献

1
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.核酸模板与 PCR 诱导的 HIV-1 耐药突变的风险。
PLoS One. 2010 Jun 7;5(6):e10992. doi: 10.1371/journal.pone.0010992.
2
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.在接受多种核苷类逆转录酶抑制剂治疗的患者中,K65R与HIV-1 C亚型病毒之间的关联。
J Antimicrob Chemother. 2017 Jul 1;72(7):2075-2082. doi: 10.1093/jac/dkx091.
3
K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.K65R 在包含 d4T 或 AZT 的一线方案治疗失败的 C 型 HIV-1 感染者分离株中的出现:Sanger 测序和 UDP 测序数据的比较。
PLoS One. 2012;7(5):e36549. doi: 10.1371/journal.pone.0036549. Epub 2012 May 16.
4
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.齐多夫定、拉米夫定和替诺福韦治疗失败后HIV-1的克隆耐药性分析
Antivir Ther. 2010;15(3):437-41. doi: 10.3851/IMP1539.
5
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.S68G 多态性是与 CRF01_AE 株中耐药突变 K65R 相关的补偿性突变。
BMC Infect Dis. 2020 Feb 11;20(1):123. doi: 10.1186/s12879-020-4836-z.
6
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.具有逆转录酶突变K65R和K65R+M184V的1型人类免疫缺陷病毒耐药性的分子机制及其对酶功能和病毒复制能力的影响。
Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46. doi: 10.1128/AAC.46.11.3437-3446.2002.
7
Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.影响1型人类免疫缺陷病毒C亚型变体中K65R耐药性产生过程中模板使用的因素。
Antivir Chem Chemother. 2010 Jan 5;20(3):117-31. doi: 10.3851/IMP1443.
8
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.使用替诺福韦与恩曲他滨组合或阿巴卡韦与拉米夫定组合进行1型人类免疫缺陷病毒的体外耐药性筛选。
Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. doi: 10.1128/AAC.00816-06. Epub 2006 Sep 18.
9
Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.核苷和核苷酸类似物在培养过程中会筛选出人类免疫缺陷病毒1型和2型不同的耐药模式。
Antimicrob Agents Chemother. 2009 Feb;53(2):708-15. doi: 10.1128/AAC.01109-08. Epub 2008 Dec 8.
10
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.HIV-1 C亚型病毒在细胞培养中对替诺福韦迅速产生K65R耐药性。
AIDS. 2006 Jun 12;20(9):F9-13. doi: 10.1097/01.aids.0000232228.88511.0b.

引用本文的文献

1
Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing.应用前病毒 DNA 基因型耐药检测优化多重耐药 HIV-1 经治患者的抗逆转录病毒治疗。
Viruses. 2023 Jun 27;15(7):1444. doi: 10.3390/v15071444.
2
Accurate estimation of molecular counts from amplicon sequence data with unique molecular identifiers.使用独特分子标识符对扩增子序列数据进行分子计数的精确估计。
Bioinformatics. 2023 Jan 1;39(1). doi: 10.1093/bioinformatics/btad002.
3
Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review.

本文引用的文献

1
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.逆转录酶中第64和65位的特征性核苷酸多态性有利于HIV-1 C亚型中K65R耐药突变的选择。
J Infect Dis. 2009 Oct 15;200(8):1202-6. doi: 10.1086/605894.
2
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.识别抗逆转录病毒疗法失败的公共卫生方法:马拉维一线抗逆转录病毒疗法失败患者中的高水平核苷类逆转录酶抑制剂耐药性
AIDS. 2009 Jun 1;23(9):1127-34. doi: 10.1097/QAD.0b013e32832ac34e.
3
印度人类免疫缺陷病毒感染者中人类免疫缺陷病毒耐药突变模式:一项范围综述。
Indian J Sex Transm Dis AIDS. 2022 Jan-Jun;43(1):13-19. doi: 10.4103/ijstd.ijstd_2_21. Epub 2022 Jun 7.
4
Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.下一代测序技术在 HIV 耐药性检测中的应用:实验室、临床和实施方面的考虑。
Viruses. 2020 Jun 5;12(6):617. doi: 10.3390/v12060617.
5
Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences.分析 HIV-1 pol 下一代序列中的异常和特征性 APOBEC 突变。
PLoS One. 2020 Feb 26;15(2):e0225352. doi: 10.1371/journal.pone.0225352. eCollection 2020.
6
Amino Acid Prevalence of HIV-1 Mutations by Direct Polymerase Chain Reaction and Single Genome Sequencing.通过直接聚合酶链反应和单基因组测序对HIV-1突变的氨基酸流行率
AIDS Res Hum Retroviruses. 2019 Oct;35(10):924-929. doi: 10.1089/AID.2018.0289. Epub 2019 Aug 26.
7
An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar.基于扩增子的测序框架,使用 PrimalSeq 和 iVar 准确测量宿主内病毒多样性。
Genome Biol. 2019 Jan 8;20(1):8. doi: 10.1186/s13059-018-1618-7.
8
A novel framework for inferring parameters of transmission from viral sequence data.一种从病毒序列数据推断传播参数的新框架。
PLoS Genet. 2018 Oct 16;14(10):e1007718. doi: 10.1371/journal.pgen.1007718. eCollection 2018 Oct.
9
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.对马拉维开始接受一线抗逆转录病毒治疗的HIV-1 C亚型阳性患者中少数耐药突变的检测。
Afr J Lab Med. 2018 May 30;7(1):708. doi: 10.4102/ajlm.v7i1.708. eCollection 2018.
10
Comparison of an Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing.比较基于新一代测序技术的诊断检测与 Sanger 测序技术在 HIV-1 基因型耐药检测中的应用。
J Clin Microbiol. 2018 May 25;56(6). doi: 10.1128/JCM.00105-18. Print 2018 Jun.
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.
模板使用情况导致在1型人类免疫缺陷病毒C亚型变体中优先获得K65R逆转录酶突变。
J Virol. 2009 Feb;83(4):2029-33. doi: 10.1128/JVI.01349-08. Epub 2008 Dec 10.
4
Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.沉默突变在HIV-1逆转录酶中被选择并影响酶活性。
AIDS. 2008 Nov 30;22(18):2501-8. doi: 10.1097/QAD.0b013e328318f16c.
5
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.在具有逆转录酶密码子215回复突变的初治抗逆转录病毒治疗人群中的1型人类免疫缺陷病毒少数变异株。
J Virol. 2008 Nov;82(21):10747-55. doi: 10.1128/JVI.01827-07. Epub 2008 Aug 20.
6
Genotypic predictors of human immunodeficiency virus type 1 drug resistance.1型人类免疫缺陷病毒耐药性的基因型预测指标
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17355-60. doi: 10.1073/pnas.0607274103. Epub 2006 Oct 25.
7
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.在博茨瓦纳接受基于去羟肌苷方案治疗的感染患者中,1型人类免疫缺陷病毒C亚型分离株中K65R突变的高流行率。
Antimicrob Agents Chemother. 2006 Dec;50(12):4182-5. doi: 10.1128/AAC.00714-06. Epub 2006 Oct 2.
8
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.HIV-1 C亚型病毒在细胞培养中对替诺福韦迅速产生K65R耐药性。
AIDS. 2006 Jun 12;20(9):F9-13. doi: 10.1097/01.aids.0000232228.88511.0b.
9
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.初治HIV感染患者对替诺福韦、阿巴卡韦和拉米夫定的早期病毒学无应答
J Infect Dis. 2005 Dec 1;192(11):1921-30. doi: 10.1086/498069. Epub 2005 Oct 25.
10
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.结构多样的核苷类似物对具有逆转录酶K65R突变的1型人类免疫缺陷病毒的体外活性
Antimicrob Agents Chemother. 2005 Mar;49(3):1139-44. doi: 10.1128/AAC.49.3.1139-1144.2005.